Actively Recruiting
Study on Gut Microbiota and Its Link to Central Serous Chorioretinopathy Comparing Bifidobacterium Supplementation to Placebo in Patients with Acute CSC
Led by Second Affiliated Hospital, School of Medicine, Zhejiang University · Updated on 2026-05-27
400
Participants Needed
1
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are investigating a possible link between gut bacteria and central serous chorioretinopathy CSC, a condition affecting the eye. This interest arose from clinical observations that many CSC patients also have chronic digestive symptoms, suggesting a connection to an imbalance in gut bacteria called dysbiosis. The study will compare gut microbiota between CSC patients and healthy people to see if there are meaningful differences. Participants diagnosed with acute CSC will be randomly assigned to one of two groups. One group will receive a supplement containing live Bifidobacterium, a beneficial gut bacteria, for at least one month. The other group will receive a placebo supplement. The study aims to evaluate whether taking Bifidobacterium supplements influences recovery speed and relapse rates compared to placebo. During the study, fecal samples will be collected for detailed microbiome analysis using whole-metagenome shotgun sequencing. Clinical outcomes, including best corrected visual acuity and various measures of retinal and choroidal thickness and vascularity, will be monitored for about one year. Participants will be followed closely to assess changes in eye health and gut microbiota composition throughout the study.
CONDITIONS
Brief Title
the Study of the Association Between the Gut Microbiota and Central Serous Chorioretinopathy
Research Team
W
Weixin Zheng, master
P
Panpan Ye, doctor
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here